Characterization of CDK(5) inhibitor, 20-223 (aka CP668863) for colorectal cancer therapy

Colorectal cancer (CRC) remains one of the leading causes of cancer related deaths in the United States. Currently, there are limited therapeutic options for patients suffering from CRC, none of which focus on the cell signaling mechanisms controlled by the popular kinase family, cyclin dependent ki...

Descripción completa

Detalles Bibliográficos
Autores principales: Robb, Caroline M., Kour, Smit, Contreras, Jacob I., Agarwal, Ekta, Barger, Carter J., Rana, Sandeep, Sonawane, Yogesh, Neilsen, Beth K., Taylor, Margaret, Kizhake, Smitha, Thakare, Rhishikesh N., Chowdhury, Sanjib, Wang, Jing, Black, Jennifer D., Hollingsworth, Michael A., Brattain, Michael G., Natarajan, Amarnath
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2017
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5797045/
https://www.ncbi.nlm.nih.gov/pubmed/29435174
http://dx.doi.org/10.18632/oncotarget.23749

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5797045/
https://www.ncbi.nlm.nih.gov/pubmed/29435174
http://dx.doi.org/10.18632/oncotarget.23749

Ejemplares similares